Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development,evidence,and recommendation
Restricted accessResearch articleFirst published online April, 2025
Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development,evidence,and recommendation
Since the publication of the original work in 2014, significant progress has been made in the characterization of genomic alterations that drive oncogenic addiction of nonsmall cell lung cancer (NSCLC) and how the immune system can leverage non-oncogenic pathways to modulate therapeutic outcomes. This update evaluates and validates the recent and emerging data for prognostic and predictive biomarkers with therapeutic targets in NSCLC.
Data sources
We performed a literature search from January 2015 to October 2023 using the keywords non-small cell lung cancer, clinical practice guidelines, gene mutations, genomic assay, immune cancer therapy, circulating tumor DNA, predictive and prognostic biomarkers, and targeted therapies.
Study selection and data extraction
We identified, reviewed, and evaluated relevant clinical trials, meta-analyses, seminal articles, and published clinical practice guidelines in the English language.
Data synthesis
Regulatory-approved targeted therapies include those somatic gene alterations of EGFR (“classic” mutations, exon 20 insertion, and rare EGFR mutations), ALK, ROS1, BRAF V600, RET, MET, NTRK, HER2, and KRAS G12C. Data for immunotherapy and circulating tumor DNA in next-generation sequencing are considered emerging, whereas the predictive role for PIK3CA gene mutation is insufficient.
Conclusions
Advances in sequencing and other genomic technologies have led to identifying novel oncogenic drivers, novel resistance mechanisms, and co-occurring mutations that characterize NSCLC, creating further therapeutic opportunities. The benefits associated with immunotherapy in the perioperative setting hold initial promise, with their long-term results awaiting.
SiegelRLMillerKDWagleNS, et al.Cancer statistics, 2023. CA Cancer J Clin2023; 73: 17–48.
2.
OwenDHSinghNIsmailaN, et al.Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO living guideline, version 2023.2. J Clin Oncol2023; 41: e63–e72.
3.
SinghNJaiyesimiIAIsmailaN, et al.Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline, version 2023.1. J Clin Oncol2023; 41: e51–e62.
4.
JaiyesimiIAOwenDHIsmailaN, et al.Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline, version 2022.3. J Clin Oncol2023; 41: e21–e30.
5.
KrisMGGasparLEChaftJE, et al.Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American society of clinical oncology/cancer care Ontario clinical practice guideline update. J Clin Oncol2017; 35: 2960–2974.
6.
DalyMESinghNIsmailaN, et al.Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol2022; 40: 1356–1384.
7.
HendriksLEKerrKMMenisJ, et al.Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol2023; 34: 339–357.
8.
PostmusPEKerrKMOudkerkM, et al.Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol2017; 28(suppl_4): iv1–iv21.
ChungCChristiansonM. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. J Oncol Pharm Pract2014; 20: 11–28.
11.
WeinsteinIBJoeAK. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol2006; 3: 448–457.
12.
MazieresJDrilonALusqueA, et al.Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol2019; 30: 1321–1328.
13.
ShollLMAisnerDLVarella-GarciaM, et al.Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience. J Thorac Oncol2015; 10: 768–777.
14.
HerbstRSMorgenszternDBoshoffC. The biology and management of non-small cell lung cancer. Nature2018; 553: 446–454.
15.
LangerCJRedmanMWWade 3rdJL, et al.SWOG S1400b (NCT02785913), a phase II study of GDC-0032 (Taselisib) for previously treated PI3K-positive patients with stage IV squamous cell lung cancer (lung-MAP sub-study). J Thorac Oncol2019; 14: 1839–1846.
16.
LewisWEHongLMottFE, et al.Efficacy of targeted inhibitors in metastatic lung squamous cell carcinoma with EGFR or ALK alterations. JTO Clin Res Rep2021; 2: 100237.
17.
RemonJBesseB. Brain metastases in oncogene-addicted non-small cell lung cancer patients: incidence and treatment. Front Oncol2018; 8: 88.
18.
YangSCYehYCChenYL, et al.Economic analysis of exclusionary EGFR test versus up-front NGS for lung adenocarcinoma in high EGFR mutation prevalence areas. J Natl Compr Cancer Netw2022; 20: 774–782.e4.
19.
ElaminYYRobichauxJPCarterBW, et al.Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell2022; 40: 754–767.e6.
20.
SoriaJCOheYVansteenkisteJ, et al.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med2018; 378: 113–125.
21.
YuHAArcilaMERekhtmanN, et al.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res2013; 19: 2240–2247.
22.
SkoulidisFHeymachJV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer2019; 19: 495–509.
23.
LuSDongXJianH, et al.AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol2022; 40: 3162–3171.
24.
SequistLVWaltmanBADias-SantagataD, et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med2011; 3: 75ra26.
25.
ShienKToyookaSYamamotoH, et al.Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res2013; 73: 3051–3061.
26.
HashidaSYamamotoHShienK, et al.Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib. Cancer Sci2015; 106: 1377–1384.
27.
GiustiniNPPatelSPMyallNJ, et al.Resistance to EGFR tyrosine kinase inhibitor therapy in non-small-cell lung cancer via newly acquired targetable oncogenic driver alterations with an emphasis on BRAF: case series and literature review of treatment. JCO Precis Oncol2022; 6: e2100551.
28.
GerberDEGandhiLCostaDB. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book2014: e353–e365.
29.
NiederstMJHuHMulveyHE, et al.The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res2015; 21: 3924–3933.
30.
ZengYYuDTianW,et al.Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer. Curr Opin Oncol2022; 34: 54–65.
31.
PetersSCamidgeDRShawAT, et al.Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med2017; 377: 829–838.
32.
CorcoranRB. Line by line: distinct patterns of anti-EGFR antibody resistance by line of therapy. J Clin Oncol2023; 41: 436–438.
33.
SequistLVHanJYAhnMJ, et al.Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol2020; 21: 373–386.
34.
GoulartBHLLarkinsEBeaverJA,et al.Continuation of third-generation tyrosine kinase inhibitors in second-line trials for EGFR-mutated non-small-cell lung cancer: regulatory considerations. J Clin Oncol2023; 41: 3905–3908.
PaoWGirardN. New driver mutations in non-small-cell lung cancer. Lancet Oncol2011; 12: 175–180.
37.
WebbTRSlavishJGeorgeRE, et al.Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther2009; 9: 331–356.
38.
ZugazagoitiaJBioscaMOliveiraJ. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer. Eur Respir J2018; 51: 1702431.
39.
LinJJZhuVWYodaS, et al.Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J Clin Oncol2018; 36: 1199–1206.
40.
ChristopoulosPEndrisVBozorgmehrF, et al.EML4-ALK Fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer. Int J Cancer2018; 142: 2589–2598.
41.
GainorJFVargheseAMOuSH, et al.ALK Rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res2013; 19: 4273–4281.
42.
ChildressMAHimmelbergSMChenH, et al.ALK fusion partners impact response to ALK inhibition: differential effects on sensitivity, cellular phenotypes, and biochemical properties. Mol Cancer Res2018; 16: 1724–1736.
43.
SolomonBJMokTKimDW, et al.First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med2014; 371: 2167–2177.
44.
CamidgeDRKimHRAhnMJ, et al.Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med2018; 379: 2027–2039.
45.
SoriaJCTanDSWChiariR, et al.First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet2017; 389: 917–929.
46.
ShawATBauerTMde MarinisF, et al.First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med2020; 383: 2018–2029.
47.
BarrowsSMWrightKCopley-MerrimanC, et al.Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer (Auckl)2019; 10: 11–20.
48.
ShawATOuSHBangYJ, et al.Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med2014; 371: 1963–1971.
49.
Garcia CampeloMRWanYLinHM, et al.Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial. Lung Cancer2023; 185: 107376.
50.
HeuckmannJMHolzelMSosML, et al.ALK Mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res2011; 17: 7394–7401.
51.
MurrayBWZhaiDDengW, et al.TPX-0131, a potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations. Mol Cancer Ther2021; 20: 1499–1507.
52.
KronAAlidoustyCSchefflerM, et al.Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol2018; 29: 2068–2075.
53.
EngJWooKMSimaCS, et al.Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas. J Thorac Oncol2015; 10: 1713–1719.
54.
BearzAMartiniJFJassemJ, et al.Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced NSCLC in relation to EML4::ALK variant type and ALK with or without TP53 mutations. J Thorac Oncol2023; 18: 1581–1593.
55.
FangWHuangYHongS, et al.EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer2019; 19: 595.
56.
AggarwalCLiuSV. Zipalertinib in EGFR exon 20-mutant non-small-cell lung cancer: drug development in a rare but crowded setting. J Clin Oncol2023; 41: 4200–4203.
57.
ZhouCRamalingamSSKimTM, et al.Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol2021; 7: e214761.
58.
ParkKHauraEBLeighlNB, et al.Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol2021; 39: 3391–3402.
59.
PiotrowskaZTanDSSmitEF, et al.Safety, tolerability, and antitumor activity of zipalertinib among patients with non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions. J Clin Oncol2023; 41: 4218–4225.
60.
WangMYangJCMitchellPL, , et al.Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. Cancer Discov2022; 12: 1676–1689.
61.
BarJPeledNSchokrpurS, et al.Uncommon EGFR mutations: international case series on efficacy of osimertinib in real-life practice in first-line setting (UNICORN). J Thorac Oncol2023; 18: 169–180.
62.
JanningMSüptitzJAlbers-LeischnerC, et al.Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol2022; 33: 602–615.
63.
RobichauxJPLeXVijayanRSK, et al.Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature2021; 597: 732–737.
64.
RussoAFranchinaTRicciardiG, et al.Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario. Int J Mol Sci2019; 20: 1431.
65.
YangJCSequistLVGeaterSL, et al.Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol2015; 16: 830–838.
66.
SimanshuDKNissleyDVMcCormickF. RAS proteins and their regulators in human disease. Cell2017; 170: 17–33.
67.
JänneP. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med2022; 387: 120–131.
68.
TanACTanDSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol2022; 40: 611–625.
69.
RobertsPJStinchcombeTE. KRAS mutation: should we test for it, and does it matter?J Clin Oncol2013; 31: 1112–1121.
70.
XueJYZhaoYAronowitzJ, et al.Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature2020; 577: 421–425.
71.
PaoWWangTYRielyGJ, , et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med2005; 2: e17.
72.
SkoulidisFLiBTDyGK, et al.Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med2021; 384: 2371–2381.
73.
de LangenAJJohnsonMLMazieresJ, et al.Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet2023; 401: 733–746.
74.
AmodioVYaegerRArcellaP, et al.EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov2020; 10: 1129–1139.
75.
LiBTFalchookGSDurmGA, et al.Codebreak 100/101: first report of safety/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC. J Thorac Oncol2022; 17: abstract OA03.06. Presented Aug 7th, 2022.
76.
JohnsonCBurkhartDLHaigisKM. Classification of KRAS-activating mutations and the implications for therapeutic intervention. Cancer Discov2022; 12: 913–923.
77.
ArbourKCLitoP. Expanding the arsenal of clinically active KRAS G12C inhibitors. J Clin Oncol2022; 40: 2609–2611.
78.
Dunnett-KaneVNicolaPBlackhallF,et al.Mechanisms of resistance to KRASG12C inhibitors. Cancers (Basel)2021; 13: 151.
79.
DrilonAJenkinsCIyerS, et al.ROS1-dependent cancers—biology, diagnostics and therapeutics. Nat Rev Clin Oncol2021; 18: 35–55.
80.
LindemanNICaglePTAisnerDL, et al.Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn2018; 20: 129–159.
81.
Muñoz-UncetaNZugazagoitiaJManzanoA, et al.High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1. Eur J Cancer2020; 141: 193–198.
82.
BergethonKShawATOuSH, et al.ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol2012; 30: 863–870.
83.
ShawATKimDWMehraR, et al.Ceritinib in ALK-rearranged non small-cell lung cancer. N Engl J Med2014; 370: 1189–1197.
84.
DrilonASienaSDziadziuszkoR, et al.Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol2020; 21: 261–270.
85.
ShawATSolomonBJChiariR, et al.Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol2019; 20: 1691–1701.
86.
YuHAPlanchardDLovlyCM. Sequencing therapy for genetically defined subgroups of non-small cell lung cancer. Am Soc Clin Oncol Educ Book2018; 38: 726–739.
87.
YunMRKimDHKimSY, et al.Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front-mutant ROS1-rearranged non-small cell lung cancer. Cancer Res2020; 26: 3287–3295.
88.
KeddyCShindePJonesK, et al.Resistance profile and structural modeling of next-generation ROS1 tyrosine kinase inhibitors. Mol Cancer Ther2022; 21: 336–346.
89.
Nguyen-NgocTBouchaabHAdjeiAA,et al.BRAF alterations as therapeutic targets in non-small-cell lung cancer. J Thorac Oncol2015; 10: 1396–1403.
90.
KhungerAKhungerMVelchetiV. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. Ther Adv Respir Dis2018; 12: 1753466618767611.
91.
PlanchardDKimTMMazieresJ, et al.Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol2016; 17: 642–650.
92.
CardarellaSOginoANishinoM, et al.Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res2013; 19: 4532–4540.
93.
HymanDMPuzanovISubbiahV, et al.Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med2015; 373: 726–736.
94.
PlanchardDSmitEFGroenHJM, et al.Dabrafenib plus trametinib in patients with previously untreated BRAFv600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol2017; 18: 1307–1316.
95.
KermorgantS. Rationale for cotargeting hepatocyte growth factor and epidermal growth factor receptor in recurrent/metastatic head and neck cancer. J Clin Oncol2023; 41: 3863–3866.
96.
AwadMMOxnardGRJackmanDM, et al.MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol2016; 34: 721–730.
97.
FramptonGMAliSMRosenzweigM, et al.Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov2015; 5: 850–859.
98.
VansteenkisteJFVan De KerkhoveC, et al.Capmatinib for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther2019; 19: 659–671.
99.
SadiqAAGeynismanDMSalgiaR. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol2011; 6: S1810–1.
100.
ReisHMetzenmacherMGoetzM, et al.MET expression in advanced non-small-cell lung cancer: effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy. Clin Lung Cancer2018; 19: e441–e463.
101.
GaronEBBrodrickP. Targeted therapy approaches for MET abnormalities in non-small cell lung cancer. Drugs2021; 81: 547–554.
102.
DrilonAClarkJWWeissJ, et al.Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med2020; 26: 47–51.
103.
LuSFangJLiX, , et al.Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). J Clin Oncol2020; 38(15_suppl): 9519.
104.
WolfJSetoTHanJY, et al.Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med2020; 383: 944–957.
105.
PaikPKFelipEVeillonR, et al.Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med2020; 383: 931–943.
106.
EngelmanJAZejnullahuKMitsudomiT, et al.MET Amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science2007; 316: 1039–1043.
107.
GainorJFNiederstMJLennerzJK, et al.Dramatic response to combination erlotinib and crizotinib in a patient with advanced, EGFR-mutant lung cancer harboring de novo MET amplification. J Thorac Oncol2016; 11: e83–e85.
108.
SchmidSFrühMPetersS. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?Lancet Oncol2020; 21: 320–322.
109.
RotowJKGuiPWuW, et al.Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. Clin Cancer Res2020; 26: 439–449.
110.
MulliganLM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer2014; 14: 173–186.
111.
GainorJFCuriglianoGKimDW, et al.Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol2021; 22: 959–969.
112.
DrilonAHuZILaiGGY, et al.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol2018; 15: 151–167.
113.
DrilonAOxnardGRTanDSW, et al.Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med2020; 383: 813–824.
114.
HeymachJNilssonMBHuoX, et al.Genomic mechanisms of RET inhibitor sensitivity and resistance in RET-fusion positive cancer cells. J Clin Oncol2023; 41(16 suppl): e21029.
115.
LinJJLiuSVMcCoachCE, et al.Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol2020; 31: 1725–1733.
116.
WeiXWGaoXZhangXC, et al.Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer. Thorac Cancer2020; 11: 1512–1521.
117.
DziadziuszkoRSmitEFDafniU, et al.Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol2019; 14: 1086–1094.
118.
KrisMGCamidgeDRGiacconeG, et al.Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol2015; 26: 1421–1427.
119.
HymanDMPiha-PaulSAWonH, et al.HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature2018; 554: 189–194.
120.
PrelajABottiglieriAProtoC, et al.Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program. Eur J Cancer2021; 149: 235–248.
121.
LiBGandhiLBesseB, et al.FP14.15 neratinib-based combination therapy in HER2-mutant lung adenocarcinomas: findings from two international phase 2 studies. J Thorac Oncol2021; 16: S234 [Abstract].
122.
ZhouCLiXWangQ, et al.Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase II study. J Clin Oncol2020; 38: 2753–2761.
123.
CalifanoRAbidinATariqNU, et al.Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Cancer Treat Rev2015; 41: 401–411.
124.
LiuLShaoXGaoW, et al.The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol2010; 5: 1922–1932.
125.
LiBTSmitEFGotoY, et al.Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med2022; 386: 241–251.
126.
GotoKGotoYKuboT, et al.Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol2023; 41: 4852–4863.
127.
MazieresJLafitteCRicordelC, et al.Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non-small-cell lung cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 trial. J Clin Oncol2022; 40: 719–728.
128.
HottaKAoeKKozukiT, et al.A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. J Thorac Oncol2018; 13: 273–27.
129.
LiuSMTuHYWeiXW, et al.First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial. Nat Med2023; 29: 2079–2086.
130.
MishraRPatelHAlanaziS, et al.HER3 signaling and targeted therapy in cancer. Oncol Rev2018; 12: 355.
131.
YuanMHuangLLChenJH, et al.The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther2019; 4: 61.
132.
YuHAGotoYHayashiH, et al.HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol2023; 41: 5363–5375.
133.
WangYWangYLiJ, et al.Clinical significance of PIK3CA gene in non-small-cell lung cancer: a systematic review and meta-analysis. Biomed Res Int2020; 2020: 3608241.
134.
ChenJYChengYNHanL, et al.Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. Cancer Biol Med2015; 12: 126–139.
135.
DonevISWangWYamadaT, et al.Transient PI3 K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res2011; 17: 2260–2269.
136.
SatoHYamamotoHSakaguchiM, et al.Combined inhibition of MEK and PI3 K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Cancer Sci2018; 109: 3183–3196.
137.
McGowanDRSkwarskiMBradleyKM, et al.Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: a phase I study in patients with advanced non-small cell lung carcinoma. Eur J Cancer2019; 113: 87–95.
138.
WhelerJMutchDLagerJ, et al.Phase I dose-escalation study of pilaralisib (SAR245408, XL147) in combination with paclitaxel and carboplatin in patients with solid tumors. Oncologist2017; 22: 377-e37.
139.
DoebeleRCDrilonAPaz-AresL, et al.Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol2020; 21: 271–282.
140.
DrilonA. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol2019; 30(Suppl_8): viii23–viii30.
141.
VollbrechtCLehmannALenzeD, et al.Validation and comparison of two NGS assays for the detection of EGFR T790 M resistance mutation in liquid biopsies of NSCLC patients. Oncotarget2018; 9: 18529–18539.
142.
SooRAMartiniJFvan der WekkenAJ, et al.Early circulating tumor DNA dynamics and efficacy of lorlatinib in patients with treatment-naive, advanced, ALK-positive NSCLC. J Thorac Oncol2023; 18: 1568–1580.
143.
GrayJEOkamotoISriuranpongV, et al.Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res2019; 25: 6644–6652.
144.
EttingerDSWoodDEAisnerDL, et al.NCCN Guidelines® insights: non-small cell lung cancer, version 2.2023. J Natl Compr Canc Netw2023; 21: 340–350.
145.
OxnardGRPaweletzCPKuangY, et al.Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res2014; 20: 1698–1705.
146.
GrayJThompsonJCCarpenterEL, et al.Plasma cell-free DNA genotyping: from an emerging concept to a standard-of-care tool in metastatic non-small cell lung cancer. Oncologist2021; 26: e1812–e1821.
147.
MateoJChakravartyDDienstmannR, et al.A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol2018; 29: 1895–1902.
148.
EttingerDSWoodDEAisnerDL, et al.NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw2021; 19: 254–266.
149.
LeeCKManJLordS, et al.Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol2018; 4: 210–216.
150.
MartinPSpitzmuellerAWuS, et al.Mutually exclusive expression of CD73 and PDL1 in tumors from patients (pt) with NSCLC, gastroesophageal (GE) and urothelial bladder carcinoma (UBC). J Clin Oncol2017; 35(15 suppl): 3079.
151.
RittmeyerABarlesiFWaterkampD, et al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet2017; 389: 255–265.
152.
CappuzzoFMcCleodMHusseinM, et al.IMpower130: progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann Oncol2018; 29(suppl 8): p.mdy 424.
153.
AhnM-JYangYYuH. Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thorac Oncol2016; 11(suppl): S115.
154.
LinJJChinEYeapBY, et al.Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer. J Thorac Oncol2019; 14: 135–140.
155.
DudnikEBsharaEGrubsteinA, et al.Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): outcomes with immune check-point inhibitors (ICPi). Lung Cancer2018; 124: 117–124.
156.
YuHBoyleTAZhouC, et al.PD-L1 expression in lung cancer. J Thorac Oncol2016; 11: 964–975.
157.
KimHKwonHJParkSY, et al.PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. Oncotarget2017; 8: 98524–98532.
158.
BaiRLvZXuD, et al.Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res2020; 8: 34.
159.
BorghaeiHPaz-AresLHornL, et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med2015; 373: 1627–1639.
160.
BrahmerJReckampKLBaasP, et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med2015; 373: 123–135.
161.
GaronEBRizviNAHuiR, et al.Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med2015; 372: 2018–2028.
162.
SesmaAPardoJCruellasM, et al.From tumor mutational burden to blood T cell receptor: looking for the best predictive biomarker in lung cancer treated with immunotherapy. Cancers (Basel)2020; 12: 2974.
163.
BorghaeiHLangerCJPaz-AresL, et al.Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials. Cancer2020; 126: 4867–4877.
164.
GandhiLRodríguez-AbreuDGadgeelS, et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med2018; 378: 2078–2092.
165.
ChangCHShihACCChangYH, et al.The prognostic significance of PD1 and PD-L1 gene expression in lung cancer: a meta-analysis. Front Oncol2021; 11: 759497.
166.
ZhaoYShiFZhouQ, et al.Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma. Medicine (Baltimore)2020; 99: e23172.
167.
ÖzgüroğluMKilickapSSezerA, et al.First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol2023; 24: 989–1001.
168.
HerbstRSGiacconeGde MarinisF, et al.Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med2020; 383: 1328–1339.
169.
HendriksLEKerrKMMenisJ, et al.Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol2023; 34: 358–376.
170.
ReckMRodríguez-AbreuDRobinsonAG, et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med2016; 375: 1823–1833.
171.
GogishviliMMelkadzeTMakharadzeT, et al.Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med2022; 28: 2374–2380.
172.
JohnsonMLChoBCLuftA, et al.Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol2023; 41: 1213–1227.
173.
HellmannMDPaz-AresLBernabe CaroR, et al.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med2019; 381: 2020–2031.
174.
ShollLMHirschFRHwangD, et al.The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol2020; 15: 1409–1424.
175.
YarchoanMAlbackerLAHopkinsAC, et al.PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight2019; 4: e126908.
176.
BenayedROffinMMullaneyK, et al.High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res2019; 25: 4712–4722.
177.
SesmaAPardoJCruellasM, et al.From tumor mutational burden to blood T cell receptor: looking for the best predictive biomarker in lung cancer treated with immunotherapy. Cancers (Basel)2020; 12: 2974.
178.
FancelloLGandiniSPelicciPG, et al.Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer2019; 7: 183.
179.
QiuPPoehleinCHMartonMJ, et al.Measuring tumor mutational burden (TMB) in plasma from mCRPC patients using two commercial NGS assays. Sci Rep2019; 9: 114.
180.
HellmannMDCiuleanuTEPluzanskiA, et al.Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med2018; 378: 2093–2104.
181.
MengGLiuXMaT, et al.Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis. Raza A, ed. PLoS ONE2022; 17: e0263629.
182.
GalvanoAGristinaVMalapelleU, et al.The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. ESMO Open2021; 6: 100124.
183.
YangQChenMGuJ, et al.Novel biomarkers of dynamic blood pd-l1 expression for immune checkpoint inhibitors in advanced non-small-cell lung cancer patients. Front Immunol2021; 12: 665133.
184.
SkoulidisFGoldbergMEGreenawaltDM, et al.STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov2018; 8: 822–835.
185.
ArbourKCJordanEKimHR, et al.Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin Cancer Res2018; 24: 334–340.
186.
Papillon-CavanaghSDoshiPDobrinR, et al.STK11 And KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open2020; 5: e000706.
187.
HerbstRSWuYLJohnT, et al.Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol2023; 41: 1830–1840.
188.
ReungwetwattanaTNakagawaKChoBC, et al.CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol2018 Aug 28: JCO2018783118. doi:https://doi.org/10.1200/JCO.2018.78.3118
189.
FelipEAltorkiNZhouC, et al.Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet2021; 398: 1344–1357.
190.
O’BrienMPaz-AresLMarreaudS, et al.Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol2022; 23: 1274–1286.
191.
ChaftJEDahlbergSEKhullarOV, et al.Adjuvant nivolumab in resected lung cancers (ANVIL). J Clin Oncol2018; 36: TPS8581.
192.
SpigelDRPetersSAEAhnM-J. MERMAID-2: phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy. J Thorac Oncol2021; 16: S745–S746.
193.
KerrKMTsaoMSNicholsonAG, et al.Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?J Thorac Oncol2015; 10: 985–989.
194.
CohenDHondelinkLMSolleveld-WesterinkN, et al.Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing. J Thorac Oncol2020; 15: 1000–1014.
195.
ImyanitovENIyevlevaAGLevchenkoEV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol2021; 157: 103194.
196.
RecondoGFacchinettiFOlaussenKA, et al.Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?Nat Rev Clin Oncol2018; 15: 694–708.
197.
CallesAArreguiMSuárez-GonzálezJ, et al.Unleashing a Lazarus effect with selpercatinib in a never-smoker patient with stage IV, chemo-immunotherapy refractory, RET C630Y-mutant, small-cell lung cancer: a first case report. JCO Precis Oncol2023; 7: e2300321.
198.
ParkSKimTMHanJY, et al.Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol2023 Oct 20: JCO2301891. doi:https://doi.org/10.1200/JCO.23.01891.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
